Biodesix, Inc.
- BDSX
- NASDAQ
- Medical - Diagnostics & Research
- Lung Cancer Diagnostics
- Blood-Based Biomarker Tests
$23.40
Today −1.10%Quote Oct 19, 2026, 08:00 PM UTC
−17.88%over the last month
Max drawdown −22.2%From 1-month high −22.2%3 months +19.4%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Biodesix
Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT).
Where the money comes from
Q2 2026 revenue $26.9M
- Diagnostic Tests$25.3M94.4%
- Development Services$1.5M5.6%
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Exchange
NASDAQ
Employees
334
Market value
$246.9M
Quote Oct 19
Floor
$22.14
5.4% below price
Resistance
$23.39
Price is above this level
Price vs analyst targets
9 analysts
Lowest target
$32.00Highest target
$38.00
$32.00Highest target
$38.00
- Price $23.40
- Average target $35.00
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 50% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about BDSXPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free